What is Clovis Oncology Financial Strength?
Clovis Oncology has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Clovis Oncology did not have earnings to cover the interest expense.
Clovis Oncology's debt to revenue ratio for the quarter that ended in Sep. 2022 was 5.55.
As of today, Clovis Oncology's Altman Z-Score is 0.00.
Competitive Comparison of Clovis Oncology's Financial Strength
For the Biotechnology subindustry, Clovis Oncology's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clovis Oncology's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clovis Oncology's Financial Strength distribution charts can be found below:
* The bar in red indicates where Clovis Oncology's Financial Strength falls into.
Clovis Oncology Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Clovis Oncology's Interest Expense for the
months ended in Sep. 2022 was $-9.3 Mil. Its Operating Income for the
months ended in Sep. 2022 was $-44.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $16.8 Mil.
Clovis Oncology's Interest Coverage for the quarter that ended in Sep. 2022 is
| Clovis Oncology did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Clovis Oncology's Debt to Revenue Ratio for the quarter that ended in Sep. 2022 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Clovis Oncology has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clovis Oncology (Clovis Oncology) Business Description
Traded in Other Exchanges
N/A
Address
5500 Flatiron Parkway, Suite 100, Boulder, CO, USA, 80301
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidate includes Rucaparib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company has two segments U.S and ex-U.S based on geograhic areas, with majority of its revenue coming from U.S.
Executives
| Thomas C. Harding |
officer: See Remarks |
5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
| Gillian C Ivers-read |
officer: See Remarks |
C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301 |
| Lindsey Rolfe |
officer: See remarks |
C/O CLOVIS ONCOLOGY, INC., 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158 |
| Daniel W Muehl |
officer: See remarks |
5 BILLERICA PARK, 101 BILLERICA AVE, NORTH BILLERCA MA 01862 |
| Paul Edward Gross |
officer: See Remarks |
5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80302 |
| Ronit Simantov |
director |
1988 CHAPEL STREET, NEW HAVEN CT 06515 |
| James C Blair |
director |
5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204 |
| Patrick J Mahaffy |
director, officer: President and CEO |
C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
| Thorlef Spickschen |
director |
TRAUBENWEG 25, 64342 SEEHEIN-JUGENHEIM 2M 00000 |
| Richard A. Fair |
director |
C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030 |
| Robert Azelby |
director |
307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109 |
| Hooks Corwin Dale |
officer: See remarks |
C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, BOULDER CO 80301 |
| Paul H Klingenstein |
director |
428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
| Ginger L Graham |
director |
AMYLIN PHARMACEUTICALS, INC., 885 ARAPAHOE AVENUE, BOULDER CO 80302 |
| Brian G Atwood |
director |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Clovis Oncology (Clovis Oncology) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CLVSQ has been successfully added to your